Page 102 - 《中国药房》2023年20期

W，et al. Practice guidelines for the diagnosis and manage‐ lung transplantation patients，based on therapeutic drug
ment of aspergillosis：2016 update by the Infectious Di- monitoring data[J]. J Clin Pharmacol，2022，62（10）：1310-
seases Society of America[J]. Clin Infect Dis，2016，63 1320.
（4）：e1-e60. [21] HOHMANN N，KOCHEISE F，CARLS A，et al. Dose-
[13] KULKARNI H S，WITT C A. Voriconazole in lung trans‐ dependent bioavailability and CYP3A inhibition contri-
plant recipients： how worried should we be? [J]. Am J bute to non-linear pharmacokinetics of voriconazole[J].
Transplant，2018，18（1）：5-6. Clin Pharmacokinet，2016，55（12）：1535-1545.
[14] CHANG H H，LEE N Y，KO W C，et al. Voriconazole in‐ [22] JOHNSON T N，SALEM F，JAMEI M，et al. Prediction
hibition of tacrolimus metabolism in a kidney transplant of voriconazole non-linear pharmacokinetics using a pae‐
recipient with fluconazole-resistant cryptococcal meningi‐ diatric physiologically based pharmacokinetic modelling
tis[J]. Int J Infect Dis，2010，14（4）：e348-e350. approach[J]. Clin Pharmacokinet，2015，54（5）：567-568.
[15] SUETSUGU K，MORI，YAMAMOTO N，et al. Impact of [23] KIM Y，RHEE S J，PARK W B，et al. A personalized
CYP3A5，POR，and CYP2C19 polymorphisms on trough CYP2C19 phenotype-guided dosing regimen of vorico-
concentration to dose ratio of tacrolimus in allogeneic he‐ nazole using a population pharmacokinetic analysis[J]. J
matopoietic stem cell transplantation[J]. Int J Mol Sci， Clin Med，2019，8（2）：227.
2019，20（10）：2413. [24] WEHBE E，DUNCAN A E，DAR G，et al. Recovery from
[16] VANHOVE T，BOUWSMA H，HILBRANDS L，et al. De‐ AKI and short- and long-term outcomes after lung trans‐
terminants of the magnitude of interaction between tacroli‐ plantation[J]. Clin J Am Soc Nephrol，2013，8（1）：19-25.
mus and voriconazole/posaconazole in solid organ reci- [25] SIKMA M A，HUNAULT C C，VAN DE GRAAF E A，et
pients[J]. Am J Transplant，2017，17（9）：2372-2380. al. High tacrolimus blood concentrations early after lung
[17] MORI T，KATO J，YAMANE A，et al. Drug interaction transplantation and the risk of kidney injury[J]. Eur J Clin
between voriconazole and tacrolimus and its association Pharmacol，2017，73（5）：573-580.
with the bioavailability of oral voriconazole in recipients [26] ZAPATA C M，IBRAHIM H N. Kidney disease after heart
of allogeneic hematopoietic stem cell transplantation[J]. and lung transplantation[J]. Methodist Debakey Cardio‐
Int J Hematol，2012，95（5）：564-569. vasc J，2022，18（4）：34-40.
[18] VENKATARAMANAN R，ZANG S M，GAYOWSKI T， [27] PLOSKER G L，FOSTER R H. Tacrolimus：a further up‐
et al. Voriconazole inhibition of the metabolism of tacroli‐ date of its pharmacology and therapeutic use in the ma-
mus in a liver transplant recipient and in human liver mi‐ nagement of organ transplantation[J]. Drugs，2000，59（2）：
crosomes[J]. Antimicrob Agents Chemother，2002，46（9）： 323-389.
3091-3093. [28] 官东秀，冯祚臻，俸小平，等. 伏立康唑药物不良反应文
[19] ZHAO Y C，XIAO C L，HOU J J，et al. The effect of vori‐ 献分析[J]. 齐鲁药事，2009，28（8）：507-508.
conazole on tacrolimus in kidney transplantation reci- GUAN D X，FENG Z Z，FENG X P，et al. Literature
pients：a real-world study[J]. Pharmaceutics，2022，14 analysis of adverse drug reactions of voriconazole[J]. Qilu
（12）：2739. Pharm Aff，2009，28（8）：507-508.
[20] CHEN W Q，WANG X X，LI B，et al. Effects of vorico- （收稿日期：2023-05-08 修回日期：2023-07-28）
nazole exposure on the pharmacokinetics of tacrolimus in （编辑：孙 冰）

· 2524 · China Pharmacy 2023 Vol. 34 No. 20 中国药房 2023年第34卷第20期